Vest Financial LLC Has $73.10 Million Stock Position in Abbott Laboratories $ABT

Vest Financial LLC boosted its holdings in Abbott Laboratories (NYSE:ABT) by 1.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 805,637 shares of the healthcare product maker’s stock after purchasing an additional 8,114 shares during the quarter. Abbott Laboratories comprises 0.8% of Vest Financial LLC’s holdings, making the stock its 26th largest holding. Vest Financial LLC’s holdings in Abbott Laboratories were worth $73,104,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Beta Wealth Group Inc. boosted its stake in Abbott Laboratories by 11.1% during the second quarter. Beta Wealth Group Inc. now owns 5,007 shares of the healthcare product maker’s stock worth $454,000 after acquiring an additional 502 shares in the last quarter. Mizuho Markets Cayman LP acquired a new stake in Abbott Laboratories in the second quarter worth $144,086,000. Nicholas Wealth LLC. increased its stake in Abbott Laboratories by 10.8% in the second quarter. Nicholas Wealth LLC. now owns 13,021 shares of the healthcare product maker’s stock valued at $1,182,000 after purchasing an additional 1,269 shares in the last quarter. Nilsine Partners LLC raised its holdings in shares of Abbott Laboratories by 9.4% during the second quarter. Nilsine Partners LLC now owns 7,512 shares of the healthcare product maker’s stock valued at $682,000 after purchasing an additional 647 shares during the period. Finally, Naples Global Advisors LLC boosted its position in shares of Abbott Laboratories by 3.0% during the 2nd quarter. Naples Global Advisors LLC now owns 34,018 shares of the healthcare product maker’s stock worth $3,087,000 after purchasing an additional 981 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Instinct continuous glucose sensor is now commercially shipping in the U.S. integrated with MiniMed’s Flex automated insulin-delivery system. The partnership expands Abbott’s presence in diabetes technology and could support sensor adoption and recurring revenue. MiniMed Ships MiniMed Flex With Abbott’s Smallest Instinct Sensor
• Positive Sentiment: Abbott also entered a multiyear agreement with HealthTab to distribute its Afinion 2 point-of-care analyzers through NHS-linked pharmacies in the United Kingdom. The deal may broaden access to Abbott’s HbA1c and lipid-testing products, although financial details were not disclosed. HealthTab Enters Multi-Year Collaboration Agreement with Abbott
• Neutral Sentiment: Abbott agreed to pay approximately $670 million to resolve the Gill case and claims from roughly 2,000 individuals involving specialty formulas for premature infants. The settlement resolves a portion of the litigation, including the appeal of a prior $495 million verdict, reducing uncertainty and potentially avoiding additional legal costs. Abbott denied that its products cause necrotizing enterocolitis and said regulators and medical professionals consider the formulas safe and necessary. Abbott agrees to $670 million settlement of infant formula cases
• Negative Sentiment: The settlement represents a significant cash and earnings cost and does not resolve all potential litigation related to the infant formulas. Investors may continue to assess the scope of remaining claims and the effect on Abbott’s legal reserves and profitability. Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas

Analyst Ratings Changes

Several brokerages have recently commented on ABT. Citigroup raised their target price on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Robert W. Baird began coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target on the stock. Wells Fargo & Company raised their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Royal Bank Of Canada restated an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, Bank of America cut their target price on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $118.67.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $116.62 on Friday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a market cap of $201.80 billion, a PE ratio of 37.74, a price-to-earnings-growth ratio of 2.26 and a beta of 0.59. The stock’s fifty day simple moving average is $100.08 and its two-hundred day simple moving average is $100.05. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.